Teva moves first-in-class ecopipam toward FDA decision after pediatric Phase 3 validates D1 receptor blockade
FDA has accepted Teva’s ecopipam NDA with Priority Review after Phase 3 treatment reduced the risk of tic relapse by 53% among pediatric responders.